Table 6.
Multivariate analyses of overall survival after metachronous metastases
| Number | HR | P value | |
|---|---|---|---|
| Total patients (n) | 93 | ||
| Sex | |||
| Male | 60 | 0.873 | 0.623 |
| Female | 33 | 1 | - |
| Age at metastases | |||
| < 55 | 26 | 1 | - |
| 55-69 | 38 | 1.130 | 0.718 |
| > 69 | 29 | 0.976 | 0.945 |
| Primary differentiation | |||
| G1-G2 | 59 | 1 | - |
| G3-G4 | 34 | 1.017 | 0.955 |
| Primary histological type | |||
| Non-mucinous | 80 | 1 | - |
| Mucinous | 13 | 0.806 | 0.626 |
| KRAS | |||
| Wild type | 49 | 1 | - |
| Codon 12 Mutant type | 23 | 1.046 | 0.901 |
| Codon 13 Mutant type | 21 | 1.150 | 0.704 |
| BRAF | |||
| Wild type | 91 | 1 | - |
| Mutant type | 2 | 2.255 | 0.381 |
| PIK3CA | |||
| Wild type | 78 | 1 | - |
| Mutant type | 15 | 0.818 | 0.674 |
| PTEN | |||
| Wild type | 76 | 1 | - |
| Mutant type | 17 | 0.518 | 0.101 |
| CEA at diagnosis of metastases | |||
| < 5 ng/ml | 25 | 1 | - |
| 5-200 ng/ml | 47 | 0.682 | 0.346 |
| > 200 ng/ml | 11 | 0.935 | 0.902 |
| Unknown | 10 | 1.074 | 0.897 |
| Treatment of metastases | |||
| Chemotherapy only | 21 | 1 | - |
| Chemotherapy + TACE/TAI | 31 | 1.479 | 0.284 |
| Radical surgery | 41 | 0.280 | 0.002 |
Gene type was detected based on the primary tumor. Age at metastases was based on the time metastases diagnosed. Cox-regression model was used in the multivariate analysis. HR: hazard ratio; CEA: carcinoembryonic antigen; TACE: transcatheter arterial chemoembolization; TAI: Transcatheter arterial infusion.